9,12-octadecadienoyl chloride | 7372-07-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 9,12-octadecadienoyl chloride
• 英文别名: linoleoyl chloride；octadeca-9,12-dienoyl chloride；9,12-Octadecadienoyl chloride, (9Z,12Z)-
• CAS: 7372-07-8
• 化学式: C₁₈H₃₁ClO
• 分子量: 298.897
• InChiKey: FBWMYSQUTZRHAT-UHFFFAOYSA-N

物化性质

• 沸点：
  380.8±21.0 °C(Predicted)
• 密度：
  0.929±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 储存条件：
  2-8°C，充氩

反应信息

• 作为反应物：
  描述：

  9,12-octadecadienoyl chloride 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 4.33h， 生成 (9Z,12Z)-N-(2-iodophenyl)-N-methyloctadeca-9,12-dienamide
  参考文献：
  名称：

  钯催化光致酰胺去饱和

  摘要：

  报道了一种适用于将线性酰胺转化为其 α,β-不饱和对应物的光诱导钯催化去饱和方法。该反应不需要强碱/酸或硫/硒和氧化剂试剂，可通过简单的一步操作在室温下进行。该协议表现出极大的可扩展性和功能组耐受性。反应机理已通过氘标记实验、自由基时钟、自由基捕获和动力学研究进行了研究。机理研究表明涉及芳基/烷基钯自由基中间体的自由基途径。

  DOI：

  10.1021/acs.orglett.2c02594
• 作为产物：
  描述：

  (Z,Z)-9,12-十八烷二烯酸二聚物 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 9,12-octadecadienoyl chloride
  参考文献：
  名称：

  Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids

  摘要：

  This work describes the synthesis of a series of fatty acid hydrazide derivatives of isoniazid (INH). The compounds were tested against Mycobacterium tuberculosis H37Rv (ATCC 27294) as well as INH-resistant (ATCC 35822 and 1896 HF) and rifampicin-resistant (ATCC 35338) M. tuberculosis strains. The fatty acid derivatives of INH showed high antimycobacterial potency against the studied strains, which is desirable for a pharmaceutical compound, suggesting that the increased lipophilicity of isoniazid plays an important role in its antimycobacterial activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.034

文献信息

• [EN] COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA<br/>[FR] COMPOSITION ET MÉTHODES DE TRAITEMENT D'UNE DYSKINÉSIE CILIAIRE PRIMITIVE
  申请人：TRANSLATE BIO INC

  公开号：WO2021226463A1

  公开（公告）日：2021-11-11

  The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal intermediate chain 1 (DNAI1) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAI1 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.

  本发明提供了治疗原发性纤毛运动障碍（PCD）的方法和组合物，基于mRNA疗法。用于治疗PCD的组合物包括一个包含动力蛋白纤毛中间链1（DNAI1）编码序列的mRNA，以有效剂量和给药间隔进行给药，以使PCD的至少一个症状或特征在强度、严重程度、频率上减轻，或延迟发作。提供了具有优化DNAI1编码序列的mRNA，可以在不需要修改mRNA核苷酸的情况下进行给药，以实现体内持续功能。
• CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
  申请人：Manoharan Muthiah

  公开号：US20120035115A1

  公开（公告）日：2012-02-09

  The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

  该发明涉及公式I或II的化合物：在一种实施方式中，该发明涉及化合物和用于将配体与寡核苷酸结合的过程。该发明进一步涉及治疗各种疾病和疾病的方法，例如病毒感染、细菌感染、寄生虫感染、癌症、过敏、自身免疫疾病、免疫缺陷和免疫抑制。
• Compound and use
  申请人：ICI Americas Inc.

  公开号：US04978756A1

  公开（公告）日：1990-12-18

  A compound contains a ligand group and at least one group of the general formula --XR.sub.n where X is a linking group which contains at least one hetero-atom, R is a saturated hydrocarbyl group containing at least six carbon atoms or is an unsaturated hydrocarbyl group containing at least three carbon atoms. The ligand group can be a polyhydroxyhydrocarbyl, a triazole, an imidazole, an indazole, a thiazole, an oxazole, a carbamate, an xanthate or a phthalazine. The compounds can be used to improve bonding between a metal and a coating material in contact with the metal surface. The metal may be a tire cord and the coating material rubber or a rubber composition.

  一种化合物包含一个配体基团和至少一个符合下列一般式--XR.sub.n的基团，其中X是一个含有至少一个杂原子的连接基团，R是一个饱和的含有至少六个碳原子的烃基团，或者是一个不饱和的含有至少三个碳原子的烃基团。配体基团可以是多羟基烃基、三唑、咪唑、吲唑、噻唑、噁唑、碳酸酯、硫代乙酸酯或邻苯二甲酮。这些化合物可用于改善金属与与金属表面接触的涂层材料之间的结合。金属可以是轮胎帘线，涂层材料可以是橡胶或橡胶组合物。
• LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR USE IN THE TREATMENT OF ATROPHIC VAGINITIS
  申请人：Avoscience, LLC

  公开号：US20170312246A1

  公开（公告）日：2017-11-02

  Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I′, or I″, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis.

  本文提供了脂质类呋喃、吡咯和噻吩化合物、组合物以及使用这些化合物和组合物治疗萎缩性阴道炎的方法。具体而言，本发明包括向患有萎缩性阴道炎的受试者投与化合物I、I'或I"的有效量，或者药学上可接受的组合物、盐、同位素类似物、前药或其组合物。
• MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES
  申请人：KYDONIEUS Agis

  公开号：US20150216989A1

  公开（公告）日：2015-08-06

  Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.

  揭示了用于修改生物活性物质以实现多天输送的组合物和方法，特别是通过口服或静脉注射途径。这些组合物包括将生物活性物质与具有适当长半衰期（通常超过一天）的载体结合，其中该共轭物可选地包含将载体与生物活性物质连接的间隔物。还揭示了这些共轭物的药物配方，以及延长单剂量生物活性物质输送超过一天的方法。